Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer’s (SITC) 33RD Annual Meeting

Menlo Park, CA – November 6, 2018 – Personalis, Inc., a provider of advanced genomic sequencing and analytics for immuno-oncology, today announced that the company, along with one of their collaborators, Dr. Sekwon Jang of the Inova Cancer Center, will present new data at the upcoming Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting, taking place in Washington, D.C., November 9-11, 2018.

Following is a list of abstracts that will be presented at the meeting.

Rapid Oral Abstracts

Session ID Title & Presenter
Day & Time
Location
Rapid Oral Abstracts Molecular profiling of anti-PD-1 treated melanoma patients reveals importance of assessing neoantigen burden and tumor escape mechanisms for clinical treatment

Presenter: Sekwon Jang, MD
Director, Melanoma and Cutaneous Oncology Therapeutics and Research
Inova Melanoma and Skin Cancer Center

November 9

1:40pm

Room 204ABC

Scientific Poster Presentations

 Poster Number Title & Presenter Day & Time Location

P13

Molecular profiling of anti-PD-1 treated melanoma patients reveals importance of assessing neoantigen burden and tumor escape mechanisms for clinical treatment

Presenter: Charles W. Abbott, PhD

November 9

12:45pm-2:15pm and 6:30pm-8:00pm

Hall E
P151 Improving neoantigen identification for therapeutic and diagnostic use in immuno-oncology using mass spectrometry and machine learning

Presenter: Sean M. Boyle, PhD

November 9

12:45pm-2:15pm and 6:30pm-8:00pm

Hall E
P78 More sensitive identification of T-cell receptor beta rearrangements with an augmented transcriptome method

Presenter: Eric Levy, PhD

November 10

12:20pm-1:50pm and 7:00pm-8:30pm

Hall E

Personalis will also be exhibiting during the conference (Booth #617). Representatives will be available to answer questions about the company’s cancer immunogenomics services.

About Personalis, Inc.

Personalis, Inc. is a leading precision medicine company focused on advanced NGS-based services for immuno-oncology and cancer for clinical trials and translational research. The Personalis ACE Exome and Transcriptome technology is designed to obtain the most comprehensive and accurate tumor molecular profile and each tumor’s unique immune microenvironment for immuno-oncology applications. The company’s Clinical Laboratory is GxP aligned as well as CLIA’88 and CAP accredited. Personalis is differentiated by advanced sequencing assays, algorithms and content for neoantigen characterization, customer regulatory support, and more. Visit our website at www.personalis.com and follow @PersonalisInc.

Media Contact for Personalis:
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300

2018-11-09T12:35:45+00:00